TheEdgeResearch
Home / Stocks / TOMDF

Todos Medical Ltd. (TOMDF)

OTC Healthcare Medical - Diagnostics & Research
$0.00 ▲ +0.00%
Market Cap
$14,081
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
9.89
52-Wk Range
0.000001-0.00001
CEO
Gerald E. Commissiong
Country
IL
Currency
USD

Todos Medical Ltd. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Tel Aviv, TA, IL. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $14,081. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -324.8%. Its beta of 9.89 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
-0.00
EV / EBITDA
-4.08
Gross margin
56.0%
Operating margin
-126.7%
Net margin
-324.8%
Return on equity
Debt / equity
-1.08
Current ratio
0.20
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
7
IPO date
2017-08-24
Headquarters
Tel Aviv, TA, IL
About Todos Medical Ltd.

Todos Medical Ltd. operates as an in vitro diagnostics company, concentrating on the creation and commercialization of blood tests for the early detection of cancer and Alzheimer's disease, primarily serving the United States market. The company's innovative approaches to cancer diagnostics include the Total Biochemical Infrared Analysis (TBIA), a proprietary screening technology that uses peripheral blood spectroscopy to investigate cancer's effects on the immune system. Another key offering is the Lymphocyte Proliferation Test (LPT), a diagnostic blood assay designed to assess how peripheral blood lymphocytes and monocytes react to exogenous mitogenic stimulation, which induces cell cycle entry. Their cancer product lineup includes TM-B1 and TM-B2 for breast cancer screening, alongside the TMC blood test for diagnosing colon cancer. Beyond oncology, Todos Medical is also actively developing blood-based tests for identifying neurodegenerative conditions, notably Alzheimer's disease. In addition to its diagnostic portfolio, the company markets Tollovid, a dietary supplement acting as a 3CL protease inhibitor, formulated to bolster a healthy immune response against common coronaviruses. Furthermore, Tollovir, an antiviral treatment for Covid-19, is currently progressing through Phase 2 clinical trials. Todos Medical Ltd. engages in strategic alliances, including a collaboration with Integrated Health LLC, and has various agreements in place for developing SARS-nCoV-2 screening tests and distributing specific COVID-19 test kits. The company was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

Comparable companies

Todos Medical Ltd. is most often compared with the following Healthcare names:

ACUSBIOAFBLFEBNYNDVLPEMYSFNEPTFNVNOSCRCQVRSYF
More research on TOMDF
TOMDF technical analysis TOMDF TheEdge Score Compare against peers
Open full interactive analysis & DCF →